REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that it will host a Science Talk webcast to highlight learnings from recent preclinical and clinical studies of RAS inhibitors. The webcast, to be held at 4:00 p.m. Eastern on June 17, 2021, will provide a perspective on emerging insights about RAS-addicted cancers, including the implications of common drug resistance mechanisms on targeted treatment strategies. The presentation will be led by Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, and Steve Kelsey, M.D., president, research and development.

During the event, Drs. Kelsey and Goldsmith will discuss scientific data from the field reported in the first half of 2021 relating to oncogenic RAS signaling, identification of cellular mechanisms that drive resistance to targeted RAS inhibitors, and treatment advances, limitations and new opportunities. Material will include clinical and preclinical findings reported by the company and other investigators at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, published work, and additional unreported observations regarding compounds from its RAS(ON) Inhibitor and RAS Companion Inhibitor portfolios.

Event Details:

Title:	Emerging Insights about RAS-Addicted Cancers, Drug Resistance and Treatment Strategies
Date:	June 17, 2021
Time:	4:00 p.m. Eastern

To participate in the live webcast, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. A replay of the webcast will be available for at least 14 days following the event.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding treatment strategies for RAS-addicted cancers, mechanisms that drive resistance to targeted RAS inhibitors and the characteristics of compounds from Revolution Medicines’ RAS(ON) Inhibitor and RAS Companion Inhibitor portfolios. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Revolution Medicines’ programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Revolution Medicines’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Revolution Medicines’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors